Browse > Article

Appropriate Timing of Surgery after Neoadjuvant Chemo-Radiation Therapy for Locally Advanced Rectal Cancer  

Garrer, Waheed Yousry (Surgical Oncology, National Cancer Institute, Cairo University)
Hossieny, Hisham Abd El Kader El (Radiotherapy, National Cancer Institute, Cairo University)
Gad, Zeiad Samir (Surgical Oncology, National Cancer Institute, Cairo University)
Namour, Alfred Elias (Medical Oncology departments, National Cancer Institute, Cairo University)
Amer, Sameh Mohammed Ahmed Abo (Surgical Oncology, National Cancer Institute, Cairo University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.17, no.9, 2016 , pp. 4381-4389 More about this Journal
Abstract
Background: Surgery is the corner stone for the management of rectal cancer. The purpose of this study was to demonstrate the optimal time of surgical resection after the completion of neoadjuvant chemo-radiotherapy (CRT) in treatment of locally advanced rectal cancer. Materials and Methods: This study compared 2 groups of patients with locally advanced rectal cancer, treated with neoadjuvant CRT followed by surgical resection either 6-8 weeks or 9-14 weeks after the completion of chemo-radiotherapy. The impact of delaying surgery was tested in comparison to early surgical resection after completion of chemo-radiotherapy. Results: The total significant response rate that could result in functional preservation was estimated to be 3.85% in group I and 15.4% in group II. Some 9.62% of our patients had residual malignant cells at one cm surgical margin. All those patients with positive margins at one cm were in group I (19.23%). There was less operative time in group II, but the difference between both groups was statistically insignificant (P=0.845). The difference between both groups regarding operative blood loss and intra operative blood transfusion was significantly less in group II (P=0.044). There was no statistically significant difference between both groups regarding the intra operative complications (P=0.609). The current study showed significantly less post-operative hospital stay period, and less post-operative wound infection in group II (P=0.012 and 0.017). The current study showed more tumor regression and necrosis in group II with a highly significant main effect of time F=61.7 (P<0.001). Pathological TN stage indicated better pathological tumor response in group II (P=0.04). The current study showed recurrence free survival for all cases at 18 months of 84.2%. In group I, survival rate at the same duration was 73.8%, however none of group II cases had local recurrence (censored) (P=0.031). Disease free survival (DFS) during the same duration (18 months) was 69.4 % for patients in group I and 82.3% for group II (P=0.429). Conclusions: Surgical resection delay up to 9-14 weeks after chemo-radiation was associated with better outcome and better recurrence free survival.
Keywords
Rectal cancer; timing of surgery; neoadjuvnat chemo-radiation therapy;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Crimaldi A, Huntington CR, Boselli D, et al (2016). Optimal timing of surgical resection after radiationtherapy in locally advanced rectal adenocarcinoma: An analysis of the National Cancer Database. Ann Surg Oncol, 23, 877-87.   DOI
2 D'Hoore A, Wolthuis AM, Van Cutsem E, et al (2012). Impact of interval between neoadjuvant chemoradiotherapy and TME for locally advanced rectal cancer on pathologic response and oncologic outcome. Ann Surg Oncol, 19, 2833-41.   DOI
3 da Luz Moreira A, Dietz D, Geisler DP, et al (2011). Neoadjuvant therapy for rectal cancer: the impact of longer interval between chemoradiation and surgery. J Gastrointest Surg, 15, 444-50.   DOI
4 Feig BW, Crane CH, Eng C, et al (2006). Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer. Am J Clin Oncol, 29, 219-24.   DOI
5 Fierens K, Pattyn P, Van Nieuwenhove Y, et al (2009). Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer: a systematic review and meta-analysis. Int J Cancer, 124, 2966-72.   DOI
6 Figer A, Shmueli E, Tulchinsky H, et al (2008). An interval & gt; 7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease free survival in patients with locally advanced rectal cancer. Ann Surg Oncol, 15, 2661-7.   DOI
7 Figueredo A, Wong RK, De Silva S, et al (2007). Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma. Cochrane Database Syst Rev, 2, 2102.
8 Giraudo G, and Morino M (2005). Laparoscopic total mesorectal excision-the Turin experience. Recent Results Cancer Res, 165, 167-79.
9 Glimelius B, Pahlman L (1990). Pre-or post operative radiotherapy in rectal and rectosigmoid carcinoma. Report from a randomized multicentric trial. Ann Surg, 211, 187-95.   DOI
10 Gittleman AE, Minsky BD, Wong D, et al (2004). Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. Dis Colon Rectum, 47, 279-86.   DOI
11 Glynne-Jones R, Kerr SF, Norton S (2008). Delaying surgery after neoadjuvant chemoradiotherapy for rectal cancer may reduce postoperative morbidity without compromising prognosis. Br J Surg, 95, 1534-40.   DOI
12 Gutman H, and Wasserberg N (2008). Resection margins in modern rectal cancer surgery. J Surg Oncol, 98, 611-5.   DOI
13 Hess CF, Rodel C, Wittekind C, et al (2004). German rectal cancer study group. preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med, 351, 1731-40.   DOI
14 Hochhaus A, Leitner A, Leitner A, et al (2007). A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer. Br J Cancer, 96, 912-7.   DOI
15 Nemoz CJ, Partensky C, Baulieux J, et al (1999). Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol, 17, 2396.   DOI
16 Holt A, Tran CL, Stamos MJ, et al (2006). Evaluation of safety of increased time interval between chemoradiation and resection for rectal cancer. University of California. Am J Surg, 192, 873-7.   DOI
17 Kennelly RP, Heeney A, White A, Winter DC, et al (2012). A prospective analysis of patient outcome following treatment of T3 rectal cancer with neo-adjuvant chemoradiotherapy and transanal excision. Int J Colorectal Dis, 27, 759-64.   DOI
18 Kim DY, Chang HJ, Choi HS, et al (2008). Optimal surgery time after preoperative chemoradiotherapy for locally advanced rectal cancers. Ann Surg, 248, 243-51.   DOI
19 Kulig J, Szura M, Richter P, et al (2012). Randomized clinical trial on preoperative radiotherapy 25 Gy in rectal cancer--treatment results at 5-year follow-up. Langenbecks Arch Surg, 397, 801-7.   DOI
20 Martling A, Cedermark B, Glimelius B, et al (2015). Tumour regression in the randomized Stockholm III Trial of radiotherapy regimens for rectal cancer. Br J Surg, 102, 972-8.   DOI
21 Stamm B, Fasolini F, Bouzourene H, et al (2006). Effect of timing of surgery on survival after preoperative hyperfractionated accelerated radiotherapy (HART) for locally advanced rectal cancer (LARC): is it a matter of days? Acta Oncol, 45, 1086-93.   DOI
22 Rodel C, Calvo FA, Beets GL, et al (2010). Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol, 11, 835-44.   DOI
23 Serrano A, Pellicer E, Valero G, et al (2003). Neoadjuvant radiation and chemotherapy in rectal cancer does not increase postoperative complications. Int J Colorectal Dis, 18, 495-9.   DOI
24 Smith DD, Bergsland EK, Garcia-Aguilar J, et al (2011). Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg, 254, 97-102.   DOI
25 Volk B, Wolmark N, Peter M (2000). Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum. national surgical adjuvant breast and bowel project protocol R-02. J Natl Cancer Inst, 92, 388-96.   DOI
26 Buskens CJ, Punt CJ, Geijsen DE, et al (2013). Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer. Br J Surg, 100, 933-9.   DOI
27 Wibe A, Svensson E, Myrvold HE, et al (2002). Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. Br J Surg, 89, 327-34.   DOI
28 Allegra CJ, Ursiny CS, Yothers G, et al (2009). Pre-operative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: "NSABP R-03". J Clin Oncol, 27, 5124-30.   DOI
29 Brown G, Evans J, Patel U (2011). Rectal cancer: primary staging and assessment after chemoradiotherapy. Semin Radiat Oncol, 21, 169-77.   DOI
30 Buecher B, Bardet E, Rio E, et al (2006). Negative influence of delayed surgery on survival after preoperative radiotherapy in rectal cancer. Colorectal Dis, 8, 430-5.   DOI
31 Cho CH, Kim H, Roh JK, et al (2006). Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival. Ann Surg, 244, 1024-30.   DOI
32 Cohen AM, Minsky BD, Chessin DB, et al (2005). Long-term Oncologic Outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg, 241, 829-38.   DOI
33 Cooper EJ, Jones EL, Foster JD, et al (2013). Timing of surgery after long-course neoadjuvant chemoradiotherapy for rectal cancer: a systematic review of the literature. Dis Colon Rectum, 56, 921-30.   DOI